Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Mobile health monitoring in the management of long term conditions has potential benefits for patient care, especially when coupled with active adjustment of medication dosage. We report studies of patient-led self-titration of oral glucose lowering medication (OGLM) and insulin in type 2 diabetes, and dose adjustments (including dose increases) in oral chemotherapy for metastatic colorectal or breast cancer. Monitoring compliance was high in each case, and the feasibility of patients self-titrating OGLM or insulin following an agreed treatment plan was demonstrated. Chemotherapy dose increases supported by detailed toxicity profiles collected by phone have also been demonstrated.

Original publication

DOI

10.1109/iembs.2011.6090449

Type

Journal article

Journal

Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference

Publication Date

01/2011

Volume

2011

Pages

1540 - 1543

Addresses

Department of Engineering Science, Institute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, UK. mel@robots.ox.ac.uk

Keywords

Humans, Neoplasms, Diabetes Mellitus, Type 2, Fluorouracil, Insulin, Deoxycytidine, Antimetabolites, Antineoplastic, Hypoglycemic Agents, Blood Glucose Self-Monitoring, Treatment Outcome, Drug Therapy, Computer-Assisted, Administration, Oral, Telemedicine, Dose-Response Relationship, Drug, Female